

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 1 of 2

Complete if Known

Application Number	10/004,287
Filing Date	October 23, 2001
First Named Inventor	Browner, Michelle F.
Art Unit	1624
Examiner Name	Balasubramanian, V.
Attorney Docket Number	018781-005710US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
VB	AA	US-6,207,679 B1	03/27/2001	Cuny et al.	
M	AB	US-6,258,822	07/10/2001	Geyer et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)				
VB	AC	WO	01/00610	A1	01/04/2001	Aventis Pharma Deutschland GMBH		<input type="checkbox"/>
M	AD	WO	01/30774	A1	05/03/2001	Aventis Pharma Deutschland GMBH		<input type="checkbox"/>
M	AE	WO	01/58890	A1	08/18/2001	Astrazeneca AB		<input type="checkbox"/>
M	AF	WO	01/68848	A1	09/20/2001	Aventis Pharma Deutschland GMBH		<input type="checkbox"/>
M	AG	WO	02/24679	A1	03/28/2002	Bayer Aktiengesellschaft		<input type="checkbox"/>
M	AH	WO	02/28860	A2	04/11/2002	Bristol-Myers Squibb Company		<input type="checkbox"/>
VB	AI	WO	02/30353	A2	04/18/2002	SmithKline Beecham Corporation		<input type="checkbox"/>
M	AJ	WO	02/30423	A1	04/18/2002	SmithKline Beecham Corporation		<input type="checkbox"/>
VB	AK	WO	02/41843	A2	05/30/2002	Tularik Inc. and F. Hoffmann La Roche AG		<input type="checkbox"/>
M	AL	WO	02/44153	A1	06/06/2002	Bayer Aktiengesellschaft		<input type="checkbox"/>
VB	AM	WO	02/48171	A2	08/13/2002	Signal Pharmaceuticals, Inc.		<input type="checkbox"/>
VB	AN	WO	02/060386	A2	08/08/2002	Bristol-Myers Squibb Company		<input type="checkbox"/>
M	AO	WO	02/076985	A1	10/03/2003	SmithKline Beecham Corporation		<input type="checkbox"/>

Examiner
Signature

V. Balasubramanian

Date
Considered


5/20/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/004,287		
		Filing Date	October 23, 2001		
		First Named Inventor	Browner, Michelle F.		
		Art Unit	1624		
		Examiner Name	Balasubramanian, V.		
Page	2	of	2	Attorney Docket Number	018781-005710US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M	AP	Karin, M., 1999, "The Beginning of the End: IκB Kinase (IKK) and NF-κB Activation," <i>The Journal of Biological Chemistry</i> 274(39):27339-27342	
M	AQ	Karin, M., 1999, "How NF-κB is activated: the role of the IκB kinase (IKK) complex," <i>Oncogene</i> 18:6867-6874	
M	AR	Karin and Delhase, 2000, "The IκB Kinase (IKK) and NF-κB: key elements in proinflammatory signaling," <i>Seminars in Immunology</i> 12(1):85-98 (Abstract)	
M	AS	May et al., 2000, "Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex," <i>Science</i> 289:1550-1554	
M	AT	Rossi et al., 2000, "Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase," <i>Nature</i> 403:103-108	
M	AU	Woronicz et al., 1997, " IκB Kinase-β: NF-κB Activation and Complex Formation with IκB Kinase-α and NIK," <i>Science</i> 278:866-870	

MAR 09 2004

Examiner Signature	V. Balasubramanian	Date Considered	5/20/04
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.